(Washington, D.C.) — Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; wholesalers; retail, specialty, and managed care, pharmacies; health insurance providers and other payers; pharmacists in hospitals and health systems; and
The House Ways and Means Committee will vote today on legislation that will include a so-called “delinking” policy in Medicare. Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked
Pharmacy benefit managers are proud to stand between those who pay for health care — patients, employers, and taxpayers — and drug manufacturers. To get the best value for prescription drugs, they negotiate directly with manufacturers for discounts off the
In 2019, over 3.6 billion prescriptions were filled in retail pharmacies by people with insurance. That’s a lot of prescriptions being filled every day, so it’s important that patients are able to pick up their prescriptions at the pharmacy counter
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on passage of prescription drug legislation in New Jersey. “PCMA applauds the New Jersey Assembly for passing S2690 / A3993 / A 2214, legislation that will help ensure New
The pharmacy benefit company market is competitive and diverse, with more than 70 full-service PBMs of varying size operating across the country. These companies differentiate themselves through the services, contract terms, and products they offer. Across this competitive industry is a common mission
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the New York Senate Investigations and Government Operations Committee’s report on pharmacy benefit managers (PBMs). “This report attempts to undermine the only industry that is reducing prescription drug
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Energy and Commerce Subcommittee on Health hearing: “Lowering Prescription Drug Prices: Deconstructing the Drug Supply Chain:” “We stand with Congress and the
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today released the following statement on the Senate Finance Committee hearing, “Drug Pricing in America: A Prescription for Change, Part III:” “We applaud the Senate Finance Committee
©2024 PCMA. All Rights Reserved.
